BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 5, 2026
Home » Topics » Briefs

Briefs
Briefs RSS Feed RSS

Regulatory actions for March 31, 2023

March 31, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akebia, Akero, Algo, Athos, Comanche, Decibel, Immvira, Merck & Co., Pacira, Pathovax, Renovion, Vistagen.
Read More

Other news to note for March 31, 2023

March 31, 2023
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Astellas, Immunoprecise, Immusoft, Psilera, Trevena, Xyphos.
Read More

In the clinic for March 31, 2023

March 31, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actinogen, Aldeyra, Asklepios, Atreca, Avalyn, Avidity, BMS, Bolt, Immutep, Janssen, Medicenna, Nanoscope, Oxford Vacmedix, PDS, Renovorx, Seelos, Sustained, Takeda, Tonix, Vaxcyte, Vyne.
Read More

Financings for March 31, 2023

March 31, 2023
Biopharmas raising money in public or private financings, including: Alligator, Aptevo, Checkpoint, Medexus, Renovorx, TC, Xoma, Zealand.
Read More

Appointments and advancements for March 31, 2023

March 31, 2023
New hires and promotions in the biopharma industry, including: Alaunos, Biocryst, Sensorion, Tscan.
Read More

Regulatory actions for March 30, 2023

March 30, 2023
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbott, Aevice Health, Bioretec.
Read More

Other news to note for March 30, 2023

March 30, 2023
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ad Astra Diagnostics, Bigfoot Biomedical, FVRS, Fundamentalvr, Haply, Illumina, Sonex, Stilla.
Read More

In the clinic for March 30, 2023

March 30, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: C2n Diagnostics, Ciliatech, Vaxxas.
Read More

Financings for March 30, 2023

March 30, 2023
Med-tech firms raising money in public or private financings, including: Delcath Systems, Watershed Informatics.
Read More

Appointments and advancements for March 30, 2023

March 30, 2023
New hires and promotions in the med-tech industry, including: American Laboratory Products, NEC Corp. of America, Somalogic, Supira Medical.
Read More
Previous 1 2 … 817 818 819 820 821 822 823 824 825 … 1790 1791 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 4, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Auvelity

    Axsome’s Auvelity cleared for large Alzheimer’s agitation market

    BioWorld
    Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
  • Pancreas

    Sonire starts US study of cancer HIFU after $18M series A

    BioWorld
    Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
  • Xray showing lung cancer on tablet

    How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III

    BioWorld
    Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing